Platelet Membrane-Camouflaged Silver Metal–Organic Framework Biomimetic Nanoparticles for the Treatment of Triple-Negative Breast Cancer
Molecular Pharmaceutics · 01.07.2024 · 21 (7) · 3577-3590
DOI: 10.1021/acs.molpharmaceut.4c00307 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 10.06.2024. Verfasst von Haiting Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P. R. China. Hauptthemen laut MEDLINE: Metal-Organic Frameworks, Triple Negative Breast Neoplasms, Silver, Apoptosis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Fundamental Research Funds for Central Universities of the Central South University, Natural Science Foundation of Hunan Province, Xiangya Hospital, Central South University.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is characterized by high malignancy and limited treatment options. Given the pressing need for more effective treatments for TNBC, this study aimed to develop platelet membrane (PM)-camouflaged silver metal-organic framework nanoparticles (PM@MOF-Ag NPs), a biomimetic nanodrug. PM@MOF-Ag NP construction involved the utilization of 2-methylimidazole and silver nitrate to prepare silver metal-organic framework (MOF-Ag) NPs. The PM@MOF-Ag NPs, due to their camouflage, possess excellent blood compatibility, immune escape ability, and a strong affinity for 4T1 tumor cells. This enhances their circulation time in vivo and promotes the aggregation of PM@MOF-Ag NPs at the 4T1 tumor site. Importantly, PM@MOF-Ag NPs demonstrated promising antitumor activity in vitro and in vivo. We further revealed that PM@MOF-Ag NPs induced tumor cell death by overproducing reactive oxygen species and promoting cell apoptosis. Moreover, PM@MOF-Ag NPs enhanced apoptosis by upregulating the ratios of Bax/Bcl-2 and cleaved caspase3/pro-caspase3. Notably, PM@MOF-Ag NPs exhibited no significant organ toxicity, whereas the administration of MOF-Ag NPs resulted in liver inflammation compared to the control group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P. R. China.
- Department of Orthopedics, Changsha Hospital of Traditional Chinese Medicine, Changsha Eighth Hospital, Changsha, Hunan 410013, P. R. China.
- Guangzhou Customs District Technology Center, Guangzhou 510700, China.
ORCID-Profile: Haiting Liu
Förderung
- Fundamental Research Funds for Central Universities of the Central South University
- Natural Science Foundation of Hunan Province
- Xiangya Hospital, Central South University
- National Natural Science Foundation of China
Zitieren
APA
Liu, H., Cai, G., Yuan, S., Zhou, X., Gui, R., & Huang, R. (2024). Platelet Membrane-Camouflaged Silver Metal–Organic Framework Biomimetic Nanoparticles for the Treatment of Triple-Negative Breast Cancer. Molecular Pharmaceutics, 21(7), 3577-3590. https://doi.org/10.1021/acs.molpharmaceut.4c00307
Vancouver
Liu H, Cai G, Yuan S, Zhou X, Gui R, Huang R. Platelet Membrane-Camouflaged Silver Metal–Organic Framework Biomimetic Nanoparticles for the Treatment of Triple-Negative Breast Cancer. Molecular Pharmaceutics. 2024;21(7):3577-3590. doi:10.1021/acs.molpharmaceut.4c00307
BibTeX
@article{Liu2024,
author = {Liu, Haiting and Cai, Guangqing and Yuan, Shuai and Zhou, Xionghui and Gui, Rong and Huang, Rong},
title = {Platelet Membrane-Camouflaged Silver Metal–Organic Framework Biomimetic Nanoparticles for the Treatment of Triple-Negative Breast Cancer},
journal = {Molecular Pharmaceutics},
year = {2024},
volume = {21},
number = {7},
pages = {3577--3590},
doi = {10.1021/acs.molpharmaceut.4c00307}
}
EUVIMED